{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056893","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.363520+00:00","generated_at":"2026-06-02T04:51:36.524346+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Gyre Therapeutics Q1 2024 revenue $27.2M, net income $9.9M; F351 Phase3 data due early 2025","bullets":["Revenue $27.2M (+9% YoY); net income $9.9M vs $4.2M; ETUARY sales $26.9M (+10% YoY).","Cash $29.8M as of March 31, 2024 (from $33.5M at Dec 2023); expects >12 months runway.","Phase 3 F351 for CHB liver fibrosis on track; topline data expected by early 2025.","U.S. IND for F351 in NASH fibrosis expected late 2024; Phase 2a trial planned in 2025.","Acquired nintedanib rights from Jiangsu Wangao to strengthen PRC pulmonary fibrosis franchise."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056893","json":"https://secwatch.observer/filing/0000950170-24-056893.json","markdown":"https://secwatch.observer/filing/0000950170-24-056893.md","text":"https://secwatch.observer/filing/0000950170-24-056893.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000095017024056893/0000950170-24-056893-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000095017024056893/gyre-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T04:51:36.524346+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2bdf0b49635398d146ebeefd12b2d97db5bf87e7","claim":"GYRE THERAPEUTICS, INC. reported the three months ended March 31, 2024 results: revenue $27.2 million.","evidence_excerpt":"of the condensed consolidated financial statements. Financial Results for the Quarter Ended March 31, 2024 • Revenues: For the three months ended March 31, 2024, revenues were $27.2 million as a result of Gyre’s indirect controlling interest in Gyre Pharmaceuticals. For the three months ended March 31, 2023, revenues were $24.9 million. The increase was driven by a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124105/000095017024056893/0000950170-24-056893-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$27.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}